JLJosé R. Lemos

José R. Lemos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


José R. Lemos has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Edward E. Custer

    Departments of Microbiology and Physiological Systems, Neurobiology & Program in Neuroscience, University of Massachusetts Medical School, Worcester, MA, USA

    8 shared publications
  • Héctor G. Marrero

    Department of Microbiology and Physiological Systems and Program in Neuroscience, University of Massachusetts Medical School, Worcester, Massachusetts 01605

    6 shared publications
  • Govindan Dayanithi

    Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic

    5 shared publications
  • E. E. Custer

    Department of Microbiology and Physiological Systems University of Massachusetts Medical School Worcester MA USA

    4 shared publications
  • Cristina Velázquez-Marrero

    Department of Microbiology and Physiological Systems and Program in Neuroscience, University of Massachusetts Medical School, Worcester, Massachusetts 01605

    3 shared publications
  • James M. McNally

    Department of Microbiology and Physiological Systems and Program in Neuroscience, University of Massachusetts Medical School, Worcester, MA 01655Department of Microbiology and Physiological Systems and Program in Neuroscience, University of Massachusetts Medical School, Worcester, MA 01655

    3 shared publications

Latest Publications

  • Voltage‐induced Ca2+release by ryanodine receptors causes neuropeptide secretion from nerve terminals

    by Cristina Velázquez‐Marrero, Edward E. Custer, Héctor Marrero, Sonia Ortiz‐Miranda, José R. Lemos

    Depolarisation‐secretion coupling is assumed to be dependent only on extracellular calcium ([Ca2+]o). Ryanodine receptor (RyR)‐sensitive stores in hypothalamic neurohypophysial system (HNS) terminals produce sparks of intracellular calcium ([Ca2+]i) that are voltage‐dependent. We hypothesised that voltage‐elicited increases in intraterminal calcium are crucial for neuropeptide secretion from presynaptic terminals, whether from influx through voltage‐gated calcium channels and/or from such voltage‐sensitive ryanodine‐mediated calcium stores. Increases in [Ca2+]iupon depolarisation in the presence of voltage‐gated calcium channel blockers, or in the absence of [Ca2+]o, still give rise to neuropeptide secretion from HNS terminals. Even in 0 [Ca2+]o, there was nonetheless an increase in capacitance suggesting exocytosis upon depolarisation. This was blocked by antagonist concentrations of ryanodine, as was peptide secretion elicited by high K+in 0 [Ca2+]o. Furthermore, such depolarisations lead to increases in [Ca2+]i. Pre‐incubation with BAPTA‐AM resulted in > 50% inhibition of peptide secretion elicited by high K+in 0 [Ca2+]o. Nifedipine but not nicardipine inhibited both the high K+response for neuropeptide secretion and intraterminal calcium, suggesting the involvement of CaV1.1 type channels as sensors in voltage‐induced calcium release. Importantly, RyR antagonists also modulate neuropeptide release under normal physiological conditions. In conclusion, our results indicate that depolarisation‐induced neuropeptide secretion is present in the absence of external calcium, and calcium release from ryanodine‐sensitive internal stores is a significant physiological contributor to neuropeptide secretion from HNS terminals.


  • Advances in the neurophysiology of magnocellular neuroendocrine cells

    by Jeffrey G. Tasker, Masha Prager‐Khoutorsky, Ryoichi Teruyama, José R. Lemos, William E. Amstrong

    Hypothalamic magnocellular neuroendocrine cells have unique electrical properties and a remarkable capacity for morphological and synaptic plasticity. Their large somatic size, their relatively uniform and dense clustering in the supraoptic and paraventricular nuclei, and their large axon terminals in the neurohypophysis make them an attractive target for direct electrophysiological interrogation. Here, we provide a brief review of significant recent findings in the neuroplasticity and neurophysiological properties of these neurones that were presented at the symposium “Electrophysiology of Magnocellular Neurons” during the 13th World Congress on Neurohypophysial Hormones in Ein Gedi, Israel in April 2019. Magnocellular vasopressin (VP) neurones respond directly to hypertonic stimulation with membrane depolarisation, which is triggered by cell shrinkage‐induced opening of an N‐terminal‐truncated variant of transient receptor potential vanilloid type‐1 (TRPV1) channels. New findings indicate that this mechanotransduction depends on actin and microtubule cytoskeletal networks, and that direct coupling of the TRPV1 channels to microtubules is responsible for mechanical gating of the channels. Vasopressin neurones also respond to osmostimulation by activation of epithelial Na+ channels (ENaC). It was shown recently that changes in ENaC activity modulate magnocellular neurone basal firing by generating tonic changes in membrane potential. Both oxytocin and VP neurones also undergo robust excitatory synapse plasticity during chronic osmotic stimulation. Recent findings indicate that new glutamate synapses induced during chronic salt loading express highly labile Ca2+‐permeable GluA1 receptors requiring continuous dendritic protein synthesis for synapse maintenance. Finally, recordings from the uniquely tractable neurohypophysial terminals recently revealed an unexpected property of activity‐dependent neuropeptide release. A significant fraction of the voltage‐dependent neurohypophysial neurosecretion was found to be independent of Ca2+ influx through voltage‐gated Ca2+ channels. Together, these findings provide a snapshot of significant new advances in the electrophysiological signalling mechanisms and neuroplasticity of the hypothalamic‐neurohypophysial system, a system that continues to make important contributions to the field of neurophysiology.


  • Purinergic receptor types in the hypothalamic‐neurohypophysial system

    by José R. Lemos, Edward E. Custer, Sonia Ortiz‐Miranda

    Many different types of purinergic receptors are present in the Hypothalamic-Neurohypophysial System (HNS), which synthesizes and releases vasopressin and oxytocin. The specific location of purinergic receptor subtypes has important functional repercussions for neuronal activity and synaptic output. Yet, until the advent of receptor KOs, this had been hindered by the low selectivity of the available pharmacological tools. The HNS offers an excellent opportunity to differentiate the functional properties of these purinergic receptors in cell bodies vs. terminals of the same physiological system. P2X2, P2X3, P2X4 and P2X7 receptors are present in vasopressin terminals while oxytocin terminals exclusively express the P2X7 subtype. The latter is not functional in the cell bodies of the HNS. These purinergic receptor subtypes are permeable to sodium vs. calcium in varying amounts and this could play an important role in the release of vasopressin vs. oxytocin during bursting activity. Endogenous ATP and its metabolite, adenosine, have autocrine and paracrine modulatory effects on the release of these neuropeptides during physiological stimulation. Finally, we hypothesize that during such action potential bursts, ATP potentiates the release of vasopressin but not of oxytocin, and that adenosine, via A1 receptors, inhibits the release of both neuropeptides.


  • Effects of calcium and sodium on ATP‐induced vasopressin release from rat isolated neurohypophysial terminals

    by E. E. Custer, T. K. Knott, S. Ortiz‐Miranda, J. R. Lemos

    ATP receptors (P2X2, P2X3, P2X4 and P2X7) are found in neurohypophysial terminals (NHTs). These purinergic receptor subtypes are known to be cation selective. In the present study, we confirm that both sodium (Na+) and calcium (Ca2+) are permeable through these NHT purinergic receptors, although to varying degrees (91% vs 9%, respectively). Furthermore, extracellular calcium inhibits the ATP‐current magnitude. Thus, the present study aimed to determine the effects of extracellular Na+ vs Ca2+ on ATP‐induced vasopressin (AVP) release from populations of rat isolated NHTs. ATP (200 μmol L‐1) perfused exogenously for 2 minutes in Normal Locke's buffer caused an initial transient increase in AVP release followed by a sustained increase in AVP release that lasted for the duration of the ATP exposure. Replacing extracellular NaCl with N‐methyl‐d‐glucamine chloride had no apparent effect on the ATP‐induced transient increase in AVP release, although it abolished the sustained AVP release induced by ATP. Furthermore, removal of extracellular calcium resulted in no ATP‐induced transient increase in AVP release but had no effect on the delayed, sustained increase in AVP release. The ATP‐induced calcium‐dependent transient increase in AVP release was inhibited by >95% using 10 μmol L‐1 of the P2X purinergic receptor antagonist PPADS (pyridoxal‐phosphate‐6‐azophenyl‐2,4‐disulphonic acid), which is a dose sufficient to block P2X2 and P2X3 receptors but not P2X4 or P2X7 receptors. Interestingly, the ATP‐induced calcium‐independent, sodium‐dependent sustained increase in AVP release was not affected by 10 μmol L‐1 PPADS. The ATP‐induced calcium‐dependent transient increase in AVP release was not affected by the P2X7 receptor antagonist Brilliant Blue‐G (100 nmol L‐1). However, the ATP‐induced sodium‐dependent sustained AVP release was inhibited by 50%. Therefore, these results show that rat isolated NHTs exhibit a biphasic response to exogenous ATP that is differentially‐dependent on extracellular calcium and sodium. Furthermore, the initial transient release appears to be through P2X2 and/or P2X3 receptors and the sustained release is through a P2X7 receptor.


  • Open Access

    Functional ryanodine receptors in the membranes of neurohypophysial secretory granules

    by James M. McNally, Edward E. Custer, Sonia Ortiz-Miranda, Dixon J. Woodbury, Susan D. Kraner, Brian M. Salzberg, José R. Lemos

    Highly localized Ca2+ release events have been characterized in several neuronal preparations. In mouse neurohypophysial terminals (NHTs), such events, called Ca2+ syntillas, appear to emanate from a ryanodine-sensitive intracellular Ca2+ pool. Traditional sources of intracellular Ca2+ appear to be lacking in NHTs. Thus, we have tested the hypothesis that large dense core vesicles (LDCVs), which contain a substantial amount of calcium, represent the source of these syntillas. Here, using fluorescence immunolabeling and immunogold-labeled electron micrographs of NHTs, we show that type 2 ryanodine receptors (RyRs) are localized specifically to LDCVs. Furthermore, a large conductance nonspecific cation channel, which was identified previously in the vesicle membrane and has biophysical properties similar to that of an RyR, is pharmacologically affected in a manner characteristic of an RyR: it is activated in the presence of the RyR agonist ryanodine (at low concentrations) and blocked by the RyR antagonist ruthenium red. Additionally, neuropeptide release experiments show that these same RyR agonists and antagonists modulate Ca2+-elicited neuropeptide release from permeabilized NHTs. Furthermore, amperometric recording of spontaneous release events from artificial transmitter-loaded terminals corroborated these ryanodine effects. Collectively, our findings suggest that RyR-dependent syntillas could represent mobilization of Ca2+ from vesicular stores. Such localized vesicular Ca2+ release events at the precise location of exocytosis could provide a Ca2+ amplification mechanism capable of modulating neuropeptide release physiologically.


  • Open Access

    μ-Opioid Inhibition of Ca2+Currents and Secretion in Isolated Terminals of the Neurohypophysis Occurs via Ryanodine-Sensitive Ca2+Stores

    by Cristina Velázquez-Marrero, Sonia Ortiz-Miranda, Héctor G. Marrero, Edward E. Custer, Steven N. Treistman, José R. Lemos

    μ-Opioid agonists have no effect on calcium currents (ICa) in neurohypophysial terminals when recorded using the classic whole-cell patch-clamp configuration. However, μ-opioid receptor (MOR)-mediated inhibition ofICais reliably demonstrated using the perforated-patch configuration. This suggests that the MOR-signaling pathway is sensitive to intraterminal dialysis and is therefore mediated by a readily diffusible second messenger. Using the perforated patch-clamp technique and ratio-calcium-imaging methods, we describe a diffusible second messenger pathway stimulated by the MOR that inhibits voltage-gated calcium channels in isolated terminals from the rat neurohypophysis (NH). Our results show a rise in basal intracellular calcium ([Ca2+]i) in response to application of [d-Ala2-N-Me-Phe4,Gly5-ol]-Enkephalin (DAMGO), a MOR agonist, that is blocked byd-Phe-Cys-Tyr-d-Trp-Orn-Thr-Pen-Thr-NH2(CTOP), a MOR antagonist. Buffering DAMGO-induced changes in [Ca2+]iwith BAPTA-AM completely blocked the inhibition of bothICaand high-K+-induced rises in [Ca2+]idue to MOR activation, but had no effect on κ-opioid receptor (KOR)-mediated inhibition. Given the presence of ryanodine-sensitive stores in isolated terminals, we tested 8-bromo-cyclic adenosine diphosphate ribose (8Br-cADPr), a competitive inhibitor of cyclic ADP-ribose (cADPr) signaling that partially relieves DAMGO inhibition ofICaand completely relieves MOR-mediated inhibition of high-K+-induced and DAMGO-induced rises in [Ca2+]i. Furthermore, antagonist concentrations of ryanodine completely blocked MOR-induced increases in [Ca2+]iand inhibition ofICaand high-K+-induced rises in [Ca2+]iwhile not affecting KOR-mediated inhibition. Antagonist concentrations of ryanodine also blocked MOR-mediated inhibition of electrically-evoked increases in capacitance. These results strongly suggest that a key diffusible second messenger mediating the MOR-signaling pathway in NH terminals is [Ca2+]ireleased by cADPr from ryanodine-sensitive stores.


  • P2X7 Receptors in Neurohypophysial Terminals: Evidence for their Role in Arginine‐Vasopressin Secretion

    by Adolfo E. Cuadra, Edward E. Custer, Elizabeth L. Bosworth, José R. Lemos

    Arginine‐vasopressin (AVP) plays a major role in maintaining cardiovascular function and related pathologies. The mechanism involved in its release into the circulation is complex and highly regulated. Recent work has implicated the purinergic receptor, P2X7R, in a role for catecholamine‐enhanced AVP release in the rat hypothalamic‐neurohypophysial (NH) system. However, the site of P2X7R action in this endocrine system, and whether or not it directly mediates release in secretory neurons have not been determined. We hypothesized that the P2X7R is expressed and mediates AVP release in NH terminals. P2X7R function was first examined by patch‐clamp recordings in isolated NH terminals. Results revealed that subpopulations of isolated terminals displayed either high ATP‐sensitivity or low ATP‐sensitivity, the latter of which was characteristic of the rat P2X7R. Additional recordings showed that terminals showing sensitivity to the P2X7R‐selective agonist, BzATP, were further inhibited by P2X7R selective antagonists, AZ10606120 and brilliant blue‐G. In confocal micrographs from tissue sections and isolated terminals of the NH P2X7R‐immunoreactivity was found to be localized in plasma membranes. Lastly, the role of P2X7R on AVP release was tested. Our results showed that BzATP evoked sustained AVP release in NH terminals, which was inhibited by AZ10606120. Taken together, our data lead us to conclude that the P2X7R is expressed in NH terminals and corroborates its role in AVP secretion. J. Cell. Physiol. 229: 333–342, 2014.


  • Modulation/physiology of calcium channel sub-types in neurosecretory terminals

    by José R. Lemos, Sonia I. Ortiz-Miranda, Adolfo E. Cuadra, Cristina Velázquez-Marrero, Edward E. Custer, Taimur Dad, Govindan Dayanithi


  • Adenosine Trisphosphate Appears to Act via Different Receptors in Terminals Versus Somata of the Hypothalamic Neurohypophysial System

    by T. K. Knott, N. Hussy, A. E. Cuadra, R. H. Lee, S. Ortiz‐Miranda, E. E. Custer, J. R. Lemos

    ATP‐induced ionic currents were investigated in isolated terminals and somata of the hypothalamic neurohypophysial system (HNS). Both terminals and somata showed inward rectification of the ATP‐induced currents and reversal near 0 mV. In terminals, ATP dose‐dependently evoked an inactivating, inward current. However, in hypothalamic somata, ATP evoked a very slowly inactivating, inward current with a higher density, and different dose dependence (EC50 of 50 μm in somata versus 9.6 μm in terminals). The ATP‐induced currents, in both the HNS terminals and somata, were highly and reversibly inhibited by suramin, suggesting the involvement of a purinergic receptor (P2XR). However, the suramin inhibition was significantly different in the two HNS compartments (IC50 of 3.6 μm in somata versus 11.6 μm in terminals). Also, both HNS compartments show significantly different responses to the purinergic receptor agonists: ATP‐γ‐S and benzoyl‐benzoyl‐ATP. Finally, there was an initial desensitisation to ATP upon successive stimulations in the terminals, which was not observed in the somata. These differences in EC50, inactivation, desensitisation and agonist sensitivity in terminals versus somata indicate that different P2X receptors mediate the responses in these two compartments of HNS neurones. Previous work has revealed mRNA transcripts for multiple purinergic receptors in micropunches of the hypothalamus. In the HNS terminals, the P2X purinergic receptor types P2X2, 3, 4 and 7 (but not 6) have been shown to exist in AVP terminals. Immonohistochemistry now indicates that P2X4R is only present in AVP terminals and that the P2X7R is found in both AVP and oxytocin terminals and somata. We speculate that these differences in receptor types reflects the specific function of endogenous ATP in the terminals versus somata of these central nervous system neurones.